title: Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.
abstract: CD25 (interluekin-2 receptor) expression in diffuse large B-cell lymphoma (DLBCL) cells has been not examined. To characterize CD25(+) DLBCL, 123 patients, who were newly diagnosed with DLBCL, were analyzed by single-color flow cytometry (FCM). CD25-positivity was significantly  higher in DLBCL patients (n = 123; mean ± SD, 27.8 ± 30.6%) than in those with reactive lymphadenopathy (n = 16; mean ± SD, 8.6 ± 4.3%) and follicular lymphoma (n = 60; mean ± SD,  12.7 ± 12.4%). By two-color FCM, CD25/CD19 or CD25/CD20 dual positivity in DLBCL patients was shown: mean ± SD, 63.7 ± 25.5% (n = 13) and 55.0 ± 28.1% (n = 14), respectively. Eighty-two percent  of the patients with DLBCL received rituximab combined with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy. A cut-off value of 60% with CD25-positivity clearly divided patients with DLBCL into two groups: CD25-high or CD25-low DLBCL. Although clinical and immunophenotypic  features were not significantly different in both groups, the former showed a significantly poorer response and more inferior progression-free survival than the latter. CD25 may be a new prognostic marker and could be a therapeutic target in DLBCL.
authors.affiliation: Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi 329-0498, Japan. sfujiwar@jichi.ac.jp
authors.forename: Shin-ichiro
authors.initials: S
authors.lastname: Fujiwara
authors.forename: Kazuo
authors.initials: K
authors.lastname: Muroi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hirata
authors.forename: Kazuya
authors.initials: K
authors.lastname: Sato
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Matsuyama
authors.forename: Ken
authors.initials: K
authors.lastname: Ohmine
authors.forename: Takahiro
authors.initials: T
authors.lastname: Suzuki
authors.forename: Katsutoshi
authors.initials: K
authors.lastname: Ozaki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
authors.forename: Tadashi
authors.initials: T
authors.lastname: Nagai
authors.forename: Akira
authors.initials: A
authors.lastname: Tanaka
authors.forename: Keiya
authors.initials: K
authors.lastname: Ozawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: C508017:IL2RA protein, human; D053645:Interleukin-2 Receptor alpha Subunit